Skip to main content

Danish Aerospace Company A/S issues Interim report for 2025

COMPANY ANNOUNCEMENT

Odense, August 25th, 2025

Company Announcement no. 63 – 25-08-2025                                

Danish Aerospace Company A/S issues Interim report for 2025

The Board of Directors of Danish Aerospace Company A/S (DAC) have today approved the interim report for 2025. The report has not been audited. The first half of 2025 shows a much stronger result compared to the same period in 2024.

Highlights – Interim Report 2025

  • Revenue was DKK 9,8 million, while Gross Profit was DKK 7,9 million.
  • Operating Profit (EBITDA) was DKK 0,4 million, a significant increase compared to the same period last year, when EBITDA was DKK -1,65 million.
  • Net profit was DKK -0,6 million compared to DKK -1,9 million last year.
  • DAC signed a contract with the European Space Agency ESA to develop and build a prototype of a new exercise device that can be used on the Lunar Gateway space station orbiting the Moon and eventually for human missions to Mars.
  • DAC entered a new area with a subcontract with Adaptix Ltd. of UK to support the development of a ground prototype of a new 3D Bone Quality Imaging System for future use in space.
  • DAC has completed the first two models of its multifunction exercise device E4D under its ESA contract. This “proto-flight model” of E4D (the first model that will be launched) was shipped to ESA and NASA in January for final integration into the launch vehicle. E4D is currently planned for launch to ISS in early 2026.
  • DAC has entered a strategic partnership with NECAS A/S in order to develop and produce advanced technological solutions applicable across the military, space and extreme environment domains.
  • DAC has merged with its subsidiary Danish Aerospace Medical Company A/S with Danish Aerospace Company A/S as the Continuing Company. As the merged has been adopted by the general assembly after 30 June 2025 the merger has not been recognised in the Interim Financial Statements for the period 1 January – 30 June 2025.
  • In the light of the increased number of DAC shareholders the Board of directors have decided to issue quarterly trading updates starting with Q3 2025.
  • Financial guidance for fiscal year 2025 is maintained.
    • Total Revenue (incl. other income) of DKK 21-23 million; and
    • Operating profit (EBITDA) of approx. DKK 1-3 million.

CEO, Thomas A. E. Andersen, states:

“With the completion of four full models of our new multifunctional exercise equipment for astronauts, E4D, DAC has now mastered this new complex and critical technology. We look forward to enhancing our exercise technology further for use by ESA and NASA on the Lunar Gateway Space Station to orbit the Moon. In parallel, we are pursuing new areas such as 3D Bone Quality Imaging and use of our wearable technologies for national defense applications.”

Management review

In the first half of 2025, DAC completed and delivered two additional E4D models bringing the number of completed models to four, for two different customers. The delivery in January of the first proto-flight model for ESA and in August the first model for a commercial customer is another major achievement for E4D. In addition, DAC received a contract from ESA for the development of a prototype of an exercise device for the Lunar Gateway space station to orbit the Moon. This prototype will build upon E4D and add an additional jumping exercise capability to it. DAC continues to see increased interest in various DAC technologies, from almost all of the new private commercial space companies. We have recently entered a new small contract with a new one of them.

With the new subcontract with Adaptix Ltd. for support of the development of a ground prototype of a new 3D Bone Quality Imaging System for future use in space, DAC is entering a new area with significant future potential.  

The new strategic collaboration with NECAS A/S will focus on harnessing the unique synergies between NECAS’ expertise in production of electronics for the defense industry and DAC’s world-class expertise in developing medical and exercise systems as well as advanced space and extreme environment technologies.

Axiom Space’s Ax-4 mission with astronauts from Hungary, Poland, the USA and India completed a 14-day mission to ISS during which some of the crew members used DAC’s Virtual Reality equipment upgraded with a new eye-tracing capability.

DACs work on the new full Water Recovery Unit ground prototype for ESA is progressing as planned.

DAC continues to pursue new contracts with ESA and US commercial space companies, as well as within the DoD sector, especially with regard to our wearable monitoring technology.

Once again in 2025 DAC successfully passed the quality audit, which is the company’s AS/EN9100 standard, rev. D quality control system approval by Bureau Veritas.

Expectations for the year

The expectations for the year’s revenue and profit as presented in DAC’s Annual Report 2024 are maintained:

  • Total Revenue (incl. other income) of DKK 21-23 million; and
  • Operating profit (EBITDA) of approx. DKK 1-3 million.

Interim Report – Danish Aerospace Company

Attachments:

Appendix 1 – Key Figures – Interim 2025
Appendix 2 – Changes in Equity 2025
Appendix 3 – Cash Flow 2025

Note: This is a translation of the corresponding Company Announcement in Danish. In case of discrepancies between the Danish wording and the English translation, the Danish wording prevails.

For further information, please contact:

Danish Aerospace Company A/S:

Chairman of the Board of Directors Niels Heering
Mobile: +45 40 17 75 31

Thomas A.E. Andersen, CEO
Tel: +45 40 29 41 62
Mail: ta@danishaerospace.com

Certified Adviser:

Baker Tilly Corporate Finance P/S
(Company reg. (CVR) no. 40073310)
Poul Bundgaards Vej 1
DK-2500 Valby
Tel.: +45 33 45 10 00
www.bakertilly.dk

About Danish Aerospace Company A/S:

Danish Aerospace Company is a high-tech company operating in the area of advanced medical instrumentation and other engineering fields primarily within space applications. Our products are based on many years of specialized research and development. These consist of developing, integrating, and applying new as well as established medical technologies to the challenges of functioning and remaining reliable in space. These products and services bring the potential of space research and experience from space operations down to Earth for the benefit of all Mankind.

Danish Aerospace Company employs engineers and technicians who deliver full engineering, production and technical services for our customers. We specialize in customer specific design, development, manufacturing, certification, maintenance, testing, and operations.

The company has developed five generations of respiratory equipment for spaceflight, bicycle ergometers for astronauts, countermeasures, adapted several commercial medical equipment for spaceflight and has participated in the development of the minus eighty degree-celsius freezers.

The Company’s quality system is certified in obligation to BS EN ISO 9001:2015, BS EN 9100:2018 technical equivalent to AS9100D that is the acknowledged standard in the area.

www.DanishAerospace.com

Appendix 1 – Key figures – Interim 2025

 1/1-2025 –
30/6-2025

1/1-2024 –
 30/6-2024
Revenue9,775,0629,563,144
Gross profit/loss7,888,4136,461,553
Other Operating Income284,451610,643
EBITDA423,193-1,652,134
Operating profit/loss195,785-1,925,308
Net financials-938,075-350,354
Net Profit/loss for the period-570,308-1,902,003
Total assets28,158,67631,986,169
Equity7,801,0839,969,711
Share performanc

Earnings per share (DKK) 
Total number of shares
No. of shares (on average)
Closing share price (DKK)

-0.05
10,982,872
10,945,601
8.4

-0.17
10,908,330
10,908,330
2.9

Appendix 2 – Changes in Equity Interim 2025

 Share capital Reserve for development costs Reserve for foreign currency translation Retained earnings 

Total

DKK DKK DKK DKK DKK
Equity at 1 January1,090,833 3,213,361 -281,622 3,870,257 7,892,829
Capital increase7,454 0 0 471,108 478,561
Development costs for the period  610,650

 0 -610,650

 0

Depreciation, amortisation and impairment for the period0 -29,154   29,154 0
Net profit/loss for the period0 0 0 -570,308 -570,308

Equity at 30 June

1,098,287

 

3,794,857

 281,622 

3,189,561

 

7,801,083

Appendix 3 – Cash flow Interim 2025

  1/1-2025 – 1/1-2024 –
 6/30-2025 6/30-2024
 DKK DKK

Net profit/loss for the period

 

-570,308

 

-1,902,003

Adjustments 994,905 249,869
Change in working capital -386,356 2,708,533

Cash flows from operating activities before financial income and expenses

 

38,241

 

1,056,399

Financial income

 

97,813

 

165,477

Financial expenses -1,035,888 -621,564

Cash flows from operating activities

 

-889,834

 

       600,312

Purchase of intangible assets

 

-894,095

 

-686,580

Purchase of property, plant and equipment -36,635 -18,209

Cash flows from investing activities

 

-930,730

 

-704,789

Raising of loans from credit institutions -300,822      428,601
Loans to group enterprises 55,592 -357,839
Change in loans from owners and Management 1,500,000 
Capital increase 478,561 

Cash flows from financing activities

 

1,733,331

 

       70,762

Change in cash and cash equivalents

 

-97,233

 

-33,715

Cash and cash equivalents at 1 January

 

297,379

 

83,506

Cash and cash equivalents at 30 June

 

200,143

 

49,791

     

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.